zoeti spun lead global manufactur medic vaccin
livestock revenu companion anim revenu
better expect result driven oper growth propel
strong companion anim product sale attribut ztss dermatolog
franchis simparica solid top-lin growth coupl bp gross
margin expans cost effici drove ep beat
guidanc adjust fx headwind vs prior guidanc pro-rata
contribut abaxi close stock ytd
face tougher y/i comp maintain buy rate rais
price target believ solid perform continu
ztss balanc sheet remain healthi provid growth opportun
develop pipelin start bark bear fruit next coupl
nutshel adjust ep better consensu
higher estim revenu increas
beat consensu estim revenu
driven oper growth price volum ahead
estim augment bp fx tailwind companion anim oper
revenu growth driven growth
intern growth livestock sale increas oper vs
forecast driven growth intern
growth gross margin improv bp y/i bp
higher estim face easier y/i comparison
oper driven dermatolog product apoquel cytopoint
simparica stronghold well increas medic rate
market china brazil brazil oper
growth affect nation truck industri strike fx
expect impact sale strike return companion anim
growth entir driven growth dermatolog product sale
simparica grew y/i indic competit
product rimadyl pain new view
guidanc adjust fx abaxi face tougher
comp includ difficult livestock comp
guidanc adjust revenu expect
adjust ep guidanc
upsid estim might limit
confid produc solid result throughout year
page
period except per share revenueadj epsrevenueadj epsrevenueadj epsrevenueadj previou revis compani data factset estim craig-hallum capit group llc
compani data craig-hallum capit group llc estim
revenu better forecast upsid partial
off-set shortfal revenu lower forecast revenu
increasingli neglig contract manufactur segment companion
anim segment post revenu upsid partial off-set shortfal
dermatolog product revenu increas y/i
sequenti driven apoquel sale
cytopoint sale dermatolog revenu
increas y/i dermatolog sale
increas y/i dermatolog segment gener
ltm sale manag believ exceed
previous state target
simparica revenu increas y/i simparica
revenu increas y/i driven time custom
purchas sale simparica increas driven
emerg market india poland turkey uptak
simparica rebound due flea tick season well strong
demand gener sale forc expect becom
blockbust annual revenu continu work
combin sarolan activ ingredi simparica
heartworm medic expect triple-combo oral product
simparica trio market
exhibit revenu intern market
page
varianc varianc except per share c-h estimate con actualto c-h estimate c-h estimate revenu driven primarili strong companion anim salesy/i companion growth driven dermatolog product apoquel cytopoint well ay/i increas simparica sale relat timingu growth livestock sale attribut competit cattley/i continu weak dairi partial off-set growth poultri swine oper growth better anticipatedy/i oper less benefit quarter result chang revenue guidancefx companion int companion anim growth driven dermatolog portfolio simparica y/i cat increas sale vaccin revolut chinaoper oper livestock growth miss estim driven cattl swiney/i growth driven favor market condit growth canada oper number smaller emerg market well swine portfoliocontract million australiabrazilcanadachinafr germani italyjapanmexicospainuk
revenu increas y/i lower
estim oper growth beat
estim fx provid tailwind vs estim
livestock revenu increas
lower estim driven
oper growth vs estim benefit fx
vs estim saw strong growth livestock driven
grow demand anim protein new product introduct sale
companion anim revenu increas y/i
higher estim driven
oper growth vs estim fx benefit
vs estim strong companion anim growth driven
higher dermatolog new product simparica sale across variou
market well increas medic rate china brazil
countri perspect oper cc growth strongest
china mexico spain australia
oper growth flat brazil result trucker strike occur
near end zoetiss intern quarter may manag expect recov
sale ship resum earli quarter
compani data craig-hallum capit group llc estim
zoeti inc page
quarterli i/ varianceactualc-h estimate variancevari million except per growth driven strong companion anim growth internationalchang bp margin expans due easier comp inventori account spend expand mab pipelin pain renal oncolog livestockamort oper oper oper expens expect higher due abaxi acquisitionincom rate lower expect due one-tim discret item tax tax rate guidanc net incom attr incom attribut ep beat lower tax w/ remaind top-lin better gross margindilut estim spent share repurchas ebitda analysi oper incom attr
revenu speci continu reflect growth companion anim product like
apoquel cytopoint simparica driven dog cat revenu
total sale year ago poultri sale decreas bp revenu
cattl revenu decreas bp partial due increas
competit weak dairi market isnt expect improv
exhibit revenu speci
guidanc adjust fx abaxi acquisit
adjust guidanc follow
compani data factset data system craig-hallum capit group llc estim
increas price target base ev/ebitda multipl
ebitda estim project net cash
share outstand price target also support appli price-to-earnings multipl
ep estim premium ztss long-term
averag valuat support long-term discount cash flow dcf
valuat analysi use termin growth rate wacc
zoeti inc page
guidanceupdatedpreviousfi million except per oper cost sale sg interest expens andoth tax rate adj dilut net signific item andacquisition-rel dilut
believ invest zoeti involv follow risk
increas restrict ban use antibiot use growth promot
livestock fda work phase-out use medic import antibacteri
anim feed growth promot chang produc behavior increas regul
could advers impact zoetiss antibacteri product sale
lead chang underli market demand product
chang util product relat protein consumpt chang
consum spend habit diet protein consumpt could advers effect
zoeti busi
infecti diseas outbreak variou infecti diseas avian flu swine flu
etc could lead cull herd reduct use product
cash pay busi therefor chang economi input cost commod
price could neg impact produc abil buy product
industri consolid increas competit continu consolid
anim health industri could lead increas competit result price pressur
could neg impact margin profit
foreign currenc fluctuat approxim zoeti busi deriv
outsid creat foreign currenc risk
zoeti inc page
dcf analysi tax free pv valuetermin termin less compani data craig-hallum capit group llc estimatestermin growthwacc
page
zoetiscraig-hallum capit groupincom statement mm except per share kevin ellich oper oper oper tax net incom attr non-controlling incom attribut ebitda analysi oper incom attribut non-controlling oper incom attribut compani report craig-hallum capit group llc estimatesaugust requir disclosur
